ONC (BeOne Medicines) ROC (Joel Greenblatt) %: 64.39% (As of Mar. 2026)


ONC BeOne Medicines Ltd ONC
79 GF Score
Price $302.83
GF Value $367.92
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines ROC (Joel Greenblatt) %?

BeOne Medicines ONC +0.31% 79 ROC (Joel Greenblatt) % is 64.39% as of Mar. 2026. GuruFocus rates ONC with a GF Score™ of 79/100 and a GF Value™ of $367.92 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,319 Biotechnology companies, BeOne Medicines ranks better than 91.36% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. BeOne Medicines's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 64.39%.

The historical rank and industry rank for BeOne Medicines's ROC (Joel Greenblatt) % or its related term are showing as below:

ONC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -718.4   Med: -246.14   Max: 41.21
Current: 41.21

During the past 13 years, BeOne Medicines's highest ROC (Joel Greenblatt) % was 41.21%. The lowest was -718.40%. And the median was -246.14%.

ONC's ROC (Joel Greenblatt) % is ranked better than
91.36% of 1319 companies
in the Biotechnology industry
Industry Median: -291.86 vs ONC: 41.21

BeOne Medicines's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


BeOne Medicines  (NAS:ONC) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


BeOne Medicines ROC (Joel Greenblatt) % Related Terms


BeOne Medicines ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines ROC (Joel Greenblatt) % Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -266.67 -225.61 -71.56 -33.89 28.27

BeOne Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.30 18.88 35.78 48.19 64.39

ONC vs MRNA, RPRX, ROIV: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, BeOne Medicines's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's ROC (Joel Greenblatt) % falls into.


ONC
79GF Score
BeOne Medicines Ltd ONC
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(865.08 + 608.227 + 190.971) - (1324.725 + 0 + 426.114)
=-86.560999999999

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(938.019 + 681.59 + 179.65) - (1409.421 + 0 + 265.365)
=124.473

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of BeOne Medicines for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1168.408/( ( (1715.948 + max(-86.560999999999, 0)) + (1788.704 + max(124.473, 0)) )/ 2 )
=1168.408/( ( 1715.948 + 1913.177 )/ 2 )
=1168.408/1814.5625
=64.39 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 64.39% mean?
BeOne Medicines (ONC) has a ROC (Joel Greenblatt) % of 64.39% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #114 out of 1319 companies in the Biotechnology industry, placing it in the top 8.6%.
Is BeOne Medicines' ROC (Joel Greenblatt) % too high?
BeOne Medicines' current ROC (Joel Greenblatt) % is 64.39%. Based on the distribution chart, BeOne Medicines ranks #114 out of 1319 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BeOne Medicines has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' ROC (Joel Greenblatt) % compare to MRNA and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #114 out of 1319 companies for ROC (Joel Greenblatt) %. This places BeOne Medicines in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current ROC (Joel Greenblatt) % is 64.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $367.92, compared to a current price of $302.83 — trading 17.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is 64.39%. BeOne Medicines' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For BeOne Medicines (ONC), the current ROC (Joel Greenblatt) % is 64.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $302.83 is trading 17.7% below its estimated GF Value™ of $367.92. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for ONC:

  • ROC (Joel Greenblatt) %: 64.39%
  • GF Value™: $367.92 vs. price of $302.83 (17.7% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
79GF Score

Get the complete analysis for ONC

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$302.83
Price
$367.92
GF Value